{"DataElement":{"publicId":"4903809","version":"1","preferredName":"Therapeutic Procedure Children's Oncology Group Administered Protocol Number","preferredDefinition":"The identification protocol number related to the administration of therapeutic agents per Children's Oncology Group. An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group.","longName":"COG_ID_ENUM","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"4944713","version":"1","preferredName":"Therapeutic Procedure Children's Oncology Group Administered","preferredDefinition":"Information related to the administration of therapeutic agents per Children's Oncology Group. An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group.","longName":"2512834v1.0:4944711v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4944711","version":"1","preferredName":"Children's Oncology Group Administered","preferredDefinition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.:The act of having given something (e.g., a medication or test).","longName":"C39353:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Children's Oncology Group","conceptCode":"C39353","definition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D129CF1-EC6C-50D0-E050-BB89AD4334A6","latestVersionIndicator":"Yes","beginDate":"2015-08-11","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-11","modifiedBy":"ONEDATA","dateModified":"2015-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D129CF1-EC7D-50D0-E050-BB89AD4334A6","latestVersionIndicator":"Yes","beginDate":"2015-08-11","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4903775","version":"1","preferredName":"COG Protocol Identifier Number","preferredDefinition":"the identification number assigned to a COG protocol.","longName":"COG_ID_NUM_ENUM","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"A9961 (Regimen B)","valueDescription":"A9961 (Regimen B)","ValueMeaning":{"publicId":"4908791","version":"1","preferredName":"A9961 (Regimen B)","longName":"4908791","preferredDefinition":"COG Protocol ID A9961 (Regimen B): Phase III Prospective Randomized Study of Craniospinal RT Followed by 1 of 2 Adjuvant Chemo Regimens for Newly-Diagnosed Average Risk Medulloblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CE6B-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CE84-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"A9961 (Regimen A)","valueDescription":"A9961 (Regimen A)","ValueMeaning":{"publicId":"4908792","version":"1","preferredName":"A9961 (Regimen A)","longName":"4908792","preferredDefinition":"COG Protocol ID A9961 (Regimen A): Phase III Prospective Randomized Study of Craniospinal RT Followed by 1 of 2 Adjuvant Chemo Regimens for Newly-Diagnosed Average Risk Medulloblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CE8E-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CEA7-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"A9952 (Regimen B)","valueDescription":"A9952 (Regimen B)","ValueMeaning":{"publicId":"4908793","version":"1","preferredName":"A9952 (Regimen B)","longName":"4908793","preferredDefinition":"COG Protocol ID A9952 (Regimen B): Chemotherapy For Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CEB1-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CECA-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"A9952 (Regimen A)","valueDescription":"A9952 (Regimen A)","ValueMeaning":{"publicId":"4908794","version":"1","preferredName":"A9952 (Regimen A)","longName":"4908794","preferredDefinition":"COG Protocol ID A9952 (Regimen A): Chemotherapy For Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CED4-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CEEC-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"P9031 (Treatment 1)","valueDescription":"P9031 (Treatment 1)","ValueMeaning":{"publicId":"4908795","version":"1","preferredName":"P9031 (Treatment 1)","longName":"4908795","preferredDefinition":"COG Protocol ID P9031 (Treatment 1):Treatment of Children with High-Stage Medulloblastoma: Cisplatin/VP-16 Pre- vs. Post-Irradiation - A Phase III Study","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CEF7-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CF0F-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"P9031 (Treatment 2)","valueDescription":"P9031 (Treatment 2)","ValueMeaning":{"publicId":"4908796","version":"1","preferredName":"P9031 (Treatment 2)","longName":"4908796","preferredDefinition":"COG Protocol ID P9031 (Treatment 2):Treatment of Children with High-Stage Medulloblastoma: Cisplatin/VP-16 Pre- vs. Post-Irradiation - A Phase III Study","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CF1A-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CF32-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"99703","valueDescription":"99703","ValueMeaning":{"publicId":"4908821","version":"1","preferredName":"99703","longName":"4908821","preferredDefinition":"COG Protocol IC 99703:A Pilot Study of Intensive Chemotherapy with Peripheral Stem Cell Support for Infants with Malignant Brain Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CF46-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CF5F-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"99701 (Regimen B)","valueDescription":"99701 (Regimen B)","ValueMeaning":{"publicId":"4908822","version":"1","preferredName":"99701 (Regimen B)","longName":"4908822","preferredDefinition":"99701 (Regimen B): A Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed By Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CF69-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CF82-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"99701 (Regimen A)","valueDescription":"99701 (Regimen A)","ValueMeaning":{"publicId":"4908823","version":"1","preferredName":"99701 (Regimen A)","longName":"4908823","preferredDefinition":"COG Protocol ID 99701 (Regimen A): A Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed By Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CF8C-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CFA5-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0126 (Stratum 2)","valueDescription":"ACNS0126 (Stratum 2)","ValueMeaning":{"publicId":"4908827","version":"1","preferredName":"ACNS0126 (Stratum 2)","longName":"4908827","preferredDefinition":"ACNS0126 (Stratum 2): A Phase II Study of Temozolomide in the Treatment of Children with High Grade Glioma or Diffuse Intrinsic Pontine Gliomas","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CFB0-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CFC9-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0126 (Stratum 1)","valueDescription":"ACNS0126 (Stratum 1)","ValueMeaning":{"publicId":"4908828","version":"1","preferredName":"ACNS0126 (Stratum 1)","longName":"4908828","preferredDefinition":"ACNS0126 (Stratum 1): A Phase II Study of Temozolomide in the Treatment of Children with High Grade Glioma or Diffuse Intrinsic Pontine Gliomas","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CFD3-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-CFEC-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0122","valueDescription":"ACNS0122","ValueMeaning":{"publicId":"4908829","version":"1","preferredName":"ACNS0122","longName":"4908829","preferredDefinition":"COG Protocol ID ACNS0122: A Phase II Study to Assess the Ability of Neoadjuvant Chemotherapy +/- Second Look Surgery To Eliminate All Measurable Disease Prior to Radiotherapy For NGGCT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B54A9C6-CFF6-EEB8-E050-BB89AD436D43","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B54A9C6-D00F-EEB8-E050-BB89AD436D43","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0332 (Regimen D)","valueDescription":"ACNS0332 (Regimen D)","ValueMeaning":{"publicId":"4908891","version":"1","preferredName":"ACNS0332 (Regimen D)","longName":"4908891","preferredDefinition":"ACNS0332 (Regimen D): Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-773C-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7755-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0332 (Regimen C)","valueDescription":"ACNS0332 (Regimen C)","ValueMeaning":{"publicId":"4908892","version":"1","preferredName":"ACNS0332 (Regimen C)","longName":"4908892","preferredDefinition":"ACNS0332 (Regimen C): Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-775F-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7778-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0332 (Regimen B)","valueDescription":"ACNS0332 (Regimen B)","ValueMeaning":{"publicId":"4908893","version":"1","preferredName":"ACNS0332 (Regimen B)","longName":"4908893","preferredDefinition":"ACNS0332 (Regimen B): Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7782-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-779B-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0332 (Regimen A)","valueDescription":"ACNS0332 (Regimen A)","ValueMeaning":{"publicId":"4908894","version":"1","preferredName":"ACNS0332 (Regimen A)","longName":"4908894","preferredDefinition":"ACNS0332 (Regimen A): Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-77A5-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-77BE-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0423","valueDescription":"ACNS0423","ValueMeaning":{"publicId":"4908895","version":"1","preferredName":"ACNS0423","longName":"4908895","preferredDefinition":"ACNS0423: Concurrent Radiation and Temozolomide Followed By Temozolomide and Lomustine in the Treatment of High-Grade Gliomas.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-77C9-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-77E2-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0334 (Regimen B)","valueDescription":"ACNS0334 (Regimen B)","ValueMeaning":{"publicId":"4908896","version":"1","preferredName":"ACNS0334 (Regimen B)","longName":"4908896","preferredDefinition":"ACNS0334 (Regimen B): A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-77EC-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7805-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0334 (Regimen A)","valueDescription":"ACNS0334 (Regimen A)","ValueMeaning":{"publicId":"4908897","version":"1","preferredName":"ACNS0334 (Regimen A)","longName":"4908897","preferredDefinition":"ACNS0334 (Regimen A): A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-780F-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7828-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0333","valueDescription":"ACNS0333","ValueMeaning":{"publicId":"4908898","version":"1","preferredName":"ACNS0333","longName":"4908898","preferredDefinition":"ACNS0333: Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7832-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-784B-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0822 (Arm B)","valueDescription":"ACNS0822 (Arm B)","ValueMeaning":{"publicId":"4908899","version":"1","preferredName":"ACNS0822 (Arm B)","longName":"4908899","preferredDefinition":"ACNS0822 (Arm B): A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7856-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-786F-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0822 (Arm A)","valueDescription":"ACNS0822 (Arm A)","ValueMeaning":{"publicId":"4908900","version":"1","preferredName":"ACNS0822 (Arm A)","longName":"4908900","preferredDefinition":"ACNS0822 (Arm A): A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7879-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7892-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS1221","valueDescription":"ACNS1221","ValueMeaning":{"publicId":"4908937","version":"1","preferredName":"ACNS1221","longName":"4908937","preferredDefinition":"ACNS1221: A Phase II Study For The Treatment Of Non-Metastatic Desmoplastic Medulloblastoma In Children Less Than 4 Years of Age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-78AA-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-78C3-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS1123 (Stratum 2)","valueDescription":"ACNS1123 (Stratum 2)","ValueMeaning":{"publicId":"4908938","version":"1","preferredName":"ACNS1123 (Stratum 2)","longName":"4908938","preferredDefinition":"ACNS1123 (Stratum 2): Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-78CD-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-78E6-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS1123 (Stratum 1)","valueDescription":"ACNS1123 (Stratum 1)","ValueMeaning":{"publicId":"4908939","version":"1","preferredName":"ACNS1123 (Stratum 1)","longName":"4908939","preferredDefinition":"ACNS1123 (Stratum 1): Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-78F0-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7909-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AEWS1221 Regimen B","valueDescription":"AEWS1221 Regimen B","ValueMeaning":{"publicId":"4908951","version":"1","preferredName":"AEWS1221 Regimen B","longName":"4908951","preferredDefinition":"AEWS1221 Regimen B: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7937-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7950-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AEWS1221 Regimen A","valueDescription":"AEWS1221 Regimen A","ValueMeaning":{"publicId":"4908952","version":"1","preferredName":"AEWS1221 Regimen A","longName":"4908952","preferredDefinition":"AEWS1221 Regimen A: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-795A-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7973-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AEWS0031 Intensive timing","valueDescription":"AEWS0031 Intensive timing","ValueMeaning":{"publicId":"4908953","version":"1","preferredName":"AEWS0031 Intensive timing","longName":"4908953","preferredDefinition":"AEWS0031 Intensive timing: Trial of Chemotherapy Intensification through Interval Compression in Ewing's Sarcoma and Related Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-797D-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7996-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AEWS0031 Standard timing","valueDescription":"AEWS0031 Standard timing","ValueMeaning":{"publicId":"4908954","version":"1","preferredName":"AEWS0031 Standard timing","longName":"4908954","preferredDefinition":"AEWS0031 Standard timing: Trial of Chemotherapy Intensification through Interval Compression in Ewing's Sarcoma and Related Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-79A0-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-79B9-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AGCT0132","valueDescription":"AGCT0132","ValueMeaning":{"publicId":"4908968","version":"1","preferredName":"AGCT0132","longName":"4908968","preferredDefinition":"AGCT0132: A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-79F4-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7A0D-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AHOD03P1","valueDescription":"AHOD03P1","ValueMeaning":{"publicId":"4908982","version":"1","preferredName":"AHOD03P1","longName":"4908982","preferredDefinition":"AHOD03P1: Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7AEE-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7B07-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AHOD0031","valueDescription":"AHOD0031","ValueMeaning":{"publicId":"4908983","version":"1","preferredName":"AHOD0031","longName":"4908983","preferredDefinition":"AHOD0031: A Phase III Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7B11-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7B2A-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"C59704","valueDescription":"C59704","ValueMeaning":{"publicId":"4908984","version":"1","preferredName":"C59704","longName":"4908984","preferredDefinition":"C59704: Pilot Study for the Treatment of Children with Newly Diagnosed Advanced Stage Hodgkin's Disease: Upfront Dose Intensive Chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7B34-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7B4D-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"C5942","valueDescription":"C5942","ValueMeaning":{"publicId":"4908985","version":"1","preferredName":"C5942","longName":"4908985","preferredDefinition":"C5942: Comprehensive Study of Clinically Staged Hodgkin's Disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7B57-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7B70-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"P9425","valueDescription":"P9425","ValueMeaning":{"publicId":"4908986","version":"1","preferredName":"P9425","longName":"4908986","preferredDefinition":"P9425: Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7B7A-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7B93-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML0631","valueDescription":"AAML0631","ValueMeaning":{"publicId":"4909015","version":"1","preferredName":"AAML0631","longName":"4909015","preferredDefinition":"AAML0631: Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during Consolidation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7C4A-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7C63-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML0531 Arm B","valueDescription":"AAML0531 Arm B","ValueMeaning":{"publicId":"4909016","version":"1","preferredName":"AAML0531 Arm B","longName":"4909016","preferredDefinition":"AAML0531 Arm B: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7C6D-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7C86-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML0531 Arm A","valueDescription":"AAML0531 Arm A","ValueMeaning":{"publicId":"4909017","version":"1","preferredName":"AAML0531 Arm A","longName":"4909017","preferredDefinition":"AAML0531 Arm A: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7C90-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7CA9-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML0431","valueDescription":"AAML0431","ValueMeaning":{"publicId":"4909018","version":"1","preferredName":"AAML0431","longName":"4909018","preferredDefinition":"AAML0431: The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B55BDEA-7CB3-79FE-E050-BB89AD435BFB","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B55BDEA-7CCC-79FE-E050-BB89AD435BFB","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AHEP0731 Regimen H","valueDescription":"AHEP0731 Regimen H","ValueMeaning":{"publicId":"4908997","version":"1","preferredName":"AHEP0731 Regimen H","longName":"4908997","preferredDefinition":"AHEP0731 Regimen H: Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F14B-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F164-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AHEP0731 Regimen W","valueDescription":"AHEP0731 Regimen W","ValueMeaning":{"publicId":"4908998","version":"1","preferredName":"AHEP0731 Regimen W","longName":"4908998","preferredDefinition":"AHEP0731 Regimen W: Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F16E-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F187-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AHEP0731 Regimen F","valueDescription":"AHEP0731 Regimen F","ValueMeaning":{"publicId":"4908999","version":"1","preferredName":"AHEP0731 Regimen F","longName":"4908999","preferredDefinition":"AHEP0731 Regimen F: Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F191-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F1AA-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AHEP0731 Regimen T","valueDescription":"AHEP0731 Regimen T","ValueMeaning":{"publicId":"4909000","version":"1","preferredName":"AHEP0731 Regimen T","longName":"4909000","preferredDefinition":"AHEP0731 Regimen T: Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F1B4-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F1CD-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AHOD0831","valueDescription":"AHOD0831","ValueMeaning":{"publicId":"4909001","version":"1","preferredName":"AHOD0831","longName":"4909001","preferredDefinition":"AHOD0831: A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F1D7-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F1F0-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AHOD0431","valueDescription":"AHOD0431","ValueMeaning":{"publicId":"4909002","version":"1","preferredName":"AHOD0431","longName":"4909002","preferredDefinition":"AHOD0431: Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin Disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F1FA-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F213-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML1531 Low Risk","valueDescription":"AAML1531 Low Risk","ValueMeaning":{"publicId":"4909031","version":"1","preferredName":"AAML1531 Low Risk","longName":"4909031","preferredDefinition":"AAML1531 Low Risk: Risk Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F33D-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F355-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML1331 High Risk","valueDescription":"AAML1331 High Risk","ValueMeaning":{"publicId":"4909024","version":"1","preferredName":"AAML1331 High Risk","longName":"4909024","preferredDefinition":"AAML1331 High Risk: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F264-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F27D-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML1331 Low Risk","valueDescription":"AAML1331 Low Risk","ValueMeaning":{"publicId":"4909025","version":"1","preferredName":"AAML1331 Low Risk","longName":"4909025","preferredDefinition":"AAML1331 Low Risk: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F287-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F2A0-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML1031 Arm C","valueDescription":"AAML1031 Arm C","ValueMeaning":{"publicId":"4909026","version":"1","preferredName":"AAML1031 Arm C","longName":"4909026","preferredDefinition":"AAML1031 Arm C: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F2AA-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F2C3-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"AAML1531 High Risk","valueDescription":"AAML1531 High Risk","ValueMeaning":{"publicId":"4909030","version":"1","preferredName":"AAML1531 High Risk","longName":"4909030","preferredDefinition":"AAML1531 High Risk: Risk Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B569320-F31A-2BD6-E050-BB89AD4302CD","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B569320-F332-2BD6-E050-BB89AD4302CD","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0831 (Observation)","valueDescription":"ACNS0831 (Observation)","ValueMeaning":{"publicId":"4915372","version":"1","preferredName":"ACNS0831 (Observation)","longName":"4915372","preferredDefinition":"ACNS0831 (Observation): Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-65A2-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-65BB-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"A5971 (Arm B1)","valueDescription":"A5971 (Arm B1)","ValueMeaning":{"publicId":"4915383","version":"1","preferredName":"A5971 (Arm B1)","longName":"4915383","preferredDefinition":"A5971 (Arm B1): A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6642-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-665B-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"A5971 (Arm A1)","valueDescription":"A5971 (Arm A1)","ValueMeaning":{"publicId":"4915384","version":"1","preferredName":"A5971 (Arm A1)","longName":"4915384","preferredDefinition":"A5971 (Arm A1): A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6665-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-667E-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"A5971 (Arm A0)","valueDescription":"A5971 (Arm A0)","ValueMeaning":{"publicId":"4915385","version":"1","preferredName":"A5971 (Arm A0)","longName":"4915385","preferredDefinition":"A5971 (Arm A0): A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6688-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-66A1-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"A5961 (Full Intensity Arm)","valueDescription":"A5961 (Full Intensity Arm)","ValueMeaning":{"publicId":"4915386","version":"1","preferredName":"A5961 (Full Intensity Arm)","longName":"4915386","preferredDefinition":"A5961 (Full Intensity Arm): FAB LMB 96 Treatment of Mature B-Cell Lymphoma/Leukemia (A SFOP/CCG/UKCCSG Cooperative Study)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-66AB-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-66C4-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"A5961 (Reduced Intensity Arm)","valueDescription":"A5961 (Reduced Intensity Arm)","ValueMeaning":{"publicId":"4915387","version":"1","preferredName":"A5961 (Reduced Intensity Arm)","longName":"4915387","preferredDefinition":"A5961 (Reduced Intensity Arm): FAB LMB 96 Treatment of Mature B-Cell Lymphoma/Leukemia (A SFOP/CCG/UKCCSG Cooperative Study)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-66CE-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-66E7-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"A5961 (COPAD X 2)","valueDescription":"A5961 (COPAD X 2)","ValueMeaning":{"publicId":"4915388","version":"1","preferredName":"A5961 (COPAD X 2)","longName":"4915388","preferredDefinition":"A5961 (COPAD X 2): FAB LMB 96 Treatment of Mature B-Cell Lymphoma/Leukemia (A SFOP/CCG/UKCCSG Cooperative Study)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-66F1-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6709-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ANHL1131 (COP, COPADM)","valueDescription":"ANHL1131 (COP, COPADM)","ValueMeaning":{"publicId":"4915391","version":"1","preferredName":"ANHL1131 (COP, COPADM)","longName":"4915391","preferredDefinition":"ANHL1131 (COP, COPADM): Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab (IND #10385) Efficacy and Safety in High Risk Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-676B-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6784-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ANHL1131 (Standard Arm)","valueDescription":"ANHL1131 (Standard Arm)","ValueMeaning":{"publicId":"4915392","version":"1","preferredName":"ANHL1131 (Standard Arm)","longName":"4915392","preferredDefinition":"ANHL1131 (Standard Arm): Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL: Evaluation of Rituximab (IND #10385) Efficacy and Safety in High Risk Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-678E-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-67A7-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ANHL12P1","valueDescription":"ANHL12P1","ValueMeaning":{"publicId":"4915393","version":"1","preferredName":"ANHL12P1","longName":"4915393","preferredDefinition":"ANHL12P1: A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-67B1-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-67CA-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ANHL01P1 (Pilot C)","valueDescription":"ANHL01P1 (Pilot C)","ValueMeaning":{"publicId":"4915394","version":"1","preferredName":"ANHL01P1 (Pilot C)","longName":"4915394","preferredDefinition":"ANHL01P1 (Pilot C): A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-67D4-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-67ED-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ANHL01P1 (Pilot B)","valueDescription":"ANHL01P1 (Pilot B)","ValueMeaning":{"publicId":"4915395","version":"1","preferredName":"ANHL01P1 (Pilot B)","longName":"4915395","preferredDefinition":"ANHL01P1 (Pilot B): A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-67F7-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6810-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AALL0932 (B-LLy)","valueDescription":"AALL0932 (B-LLy)","ValueMeaning":{"publicId":"4915396","version":"1","preferredName":"AALL0932 (B-LLy)","longName":"4915396","preferredDefinition":"AALL0932 (B-LLy): Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-681A-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6833-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AALL0434 (Capizzi MTX)","valueDescription":"AALL0434 (Capizzi MTX)","ValueMeaning":{"publicId":"4915397","version":"1","preferredName":"AALL0434 (Capizzi MTX)","longName":"4915397","preferredDefinition":"AALL0434 (Capizzi MTX): Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-683D-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6856-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"P8719","valueDescription":"P8719","ValueMeaning":{"publicId":"4915398","version":"1","preferredName":"P8719","longName":"4915398","preferredDefinition":"P8719: Trial of Shortened Therapy without Maintenance for the Treatment of Localized Non-Hodgkin's Lymphoma - A Pediatric Oncology Group Phase III Study","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6860-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6879-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"P8314","valueDescription":"P8314","ValueMeaning":{"publicId":"4915399","version":"1","preferredName":"P8314","longName":"4915399","preferredDefinition":"P8314: Trial of Local Irradiation and Chemotherapy Versus Chemotherapy Alone for the Treatment of Localized Non-Hodgkin's Lymphoma - A Pediatric Oncology Group Phase III Study","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6883-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-689C-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ARET12P1","valueDescription":"ARET12P1","ValueMeaning":{"publicId":"4915411","version":"1","preferredName":"ARET12P1","longName":"4915411","preferredDefinition":"ARET12P1: A Multi-Institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-690F-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6928-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ARET0331","valueDescription":"ARET0331","ValueMeaning":{"publicId":"4915412","version":"1","preferredName":"ARET0331","longName":"4915412","preferredDefinition":"ARET0331: Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6932-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-694B-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ARET0321","valueDescription":"ARET0321","ValueMeaning":{"publicId":"4915413","version":"1","preferredName":"ARET0321","longName":"4915413","preferredDefinition":"ARET0321: A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6955-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-696E-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ARET0231","valueDescription":"ARET0231","ValueMeaning":{"publicId":"4915414","version":"1","preferredName":"ARET0231","longName":"4915414","preferredDefinition":"ARET0231: A Single Arm Trial of Systemic and Subtenon Chemotherapy for Groups C and D Intraocular Retinoblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6978-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6991-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ARAR0332","valueDescription":"ARAR0332","ValueMeaning":{"publicId":"4915415","version":"1","preferredName":"ARAR0332","longName":"4915415","preferredDefinition":"ARAR0332: Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-699B-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-69B4-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ARAR0331","valueDescription":"ARAR0331","ValueMeaning":{"publicId":"4915416","version":"1","preferredName":"ARAR0331","longName":"4915416","preferredDefinition":"ARAR0331: Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-69BE-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-69D7-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AOST0331","valueDescription":"AOST0331","ValueMeaning":{"publicId":"4915417","version":"1","preferredName":"AOST0331","longName":"4915417","preferredDefinition":"AOST0331: A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-69E1-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-69FA-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0532 DD-4A","valueDescription":"AREN0532 DD-4A","ValueMeaning":{"publicId":"4915431","version":"1","preferredName":"AREN0532 DD-4A","longName":"4915431","preferredDefinition":"AREN0532 DD-4A: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6A05-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6A1E-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0532 EE-4A","valueDescription":"AREN0532 EE-4A","ValueMeaning":{"publicId":"4915432","version":"1","preferredName":"AREN0532 EE-4A","longName":"4915432","preferredDefinition":"AREN0532 EE-4A: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6A28-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6A41-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0321 Regimen I","valueDescription":"AREN0321 Regimen I","ValueMeaning":{"publicId":"4915433","version":"1","preferredName":"AREN0321 Regimen I","longName":"4915433","preferredDefinition":"AREN0321 Regimen I: Treatment of High Risk Renal Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6A4B-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6A64-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0321 Revised UH-2","valueDescription":"AREN0321 Revised UH-2","ValueMeaning":{"publicId":"4915434","version":"1","preferredName":"AREN0321 Revised UH-2","longName":"4915434","preferredDefinition":"AREN0321 Revised UH-2: Treatment of High Risk Renal Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6A6E-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6A87-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0321 Revised UH-1","valueDescription":"AREN0321 Revised UH-1","ValueMeaning":{"publicId":"4915435","version":"1","preferredName":"AREN0321 Revised UH-1","longName":"4915435","preferredDefinition":"AREN0321 Revised UH-1: Treatment of High Risk Renal Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6A91-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6AAA-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0321 DD-4A","valueDescription":"AREN0321 DD-4A","ValueMeaning":{"publicId":"4915436","version":"1","preferredName":"AREN0321 DD-4A","longName":"4915436","preferredDefinition":"AREN0321 DD-4A: Treatment of High Risk Renal Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6AB4-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6ACD-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0534 Revised UH-1","valueDescription":"AREN0534 Revised UH-1","ValueMeaning":{"publicId":"4915455","version":"1","preferredName":"AREN0534 Revised UH-1","longName":"4915455","preferredDefinition":"AREN0534 Revised UH-1:Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6AD8-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6AF1-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0534 Regimen I","valueDescription":"AREN0534 Regimen I","ValueMeaning":{"publicId":"4915456","version":"1","preferredName":"AREN0534 Regimen I","longName":"4915456","preferredDefinition":"AREN0534 Regimen I: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6AFB-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6B14-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0534 DD-4A /  Regimen I","valueDescription":"AREN0534 DD-4A /  Regimen I","ValueMeaning":{"publicId":"4915457","version":"1","preferredName":"AREN0534 DD-4A /  Regimen I","longName":"4915457","preferredDefinition":"AREN0534 DD-4A /  Regimen I: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6B1E-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6B37-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0534 DD-4A / Revised UH-1","valueDescription":"AREN0534 DD-4A / Revised UH-1","ValueMeaning":{"publicId":"4915458","version":"1","preferredName":"AREN0534 DD-4A / Revised UH-1","longName":"4915458","preferredDefinition":"AREN0534 DD-4A / Revised UH-1: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6B41-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6B5A-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0534 DD-4A","valueDescription":"AREN0534 DD-4A","ValueMeaning":{"publicId":"4915459","version":"1","preferredName":"AREN0534 DD-4A","longName":"4915459","preferredDefinition":"AREN0534 DD-4A: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6B64-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6B7D-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0534 EE-4A","valueDescription":"AREN0534 EE-4A","ValueMeaning":{"publicId":"4915460","version":"1","preferredName":"AREN0534 EE-4A","longName":"4915460","preferredDefinition":"AREN0534 EE-4A: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6B87-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6BA0-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0533 DD-4A / Regimen M","valueDescription":"AREN0533 DD-4A / Regimen M","ValueMeaning":{"publicId":"4915461","version":"1","preferredName":"AREN0533 DD-4A / Regimen M","longName":"4915461","preferredDefinition":"AREN0533 DD-4A / Regimen M: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6BAA-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6BC3-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"AREN0533 DD-4A","valueDescription":"AREN0533 DD-4A","ValueMeaning":{"publicId":"4915462","version":"1","preferredName":"AREN0533 DD-4A","longName":"4915462","preferredDefinition":"AREN0533 DD-4A: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-6BCD-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B64EE41-6BE6-3B0B-E050-BB89AD433710","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"ARST0431 (VI/VDC/IE/VAC)","valueDescription":"ARST0431 (VI/VDC/IE/VAC)","ValueMeaning":{"publicId":"4903796","version":"1","preferredName":"ARST0431 (VI/VDC/IE/VAC)","longName":"4903796","preferredDefinition":"COG Protocol ID ARST0431: Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-076E-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-0787-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ARST0531 (VAC/VI)","valueDescription":"ARST0531 (VAC/VI)","ValueMeaning":{"publicId":"4903797","version":"1","preferredName":"ARST0531 (VAC/VI)","longName":"4903797","preferredDefinition":"COG Protocol ID ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-0791-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-07AA-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-0763-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ARST0531 (VAC)","valueDescription":"ARST0531 (VAC)","ValueMeaning":{"publicId":"4903798","version":"1","preferredName":"ARST0531 (VAC)","longName":"4903798","preferredDefinition":"COG Protocol ID ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-07B4-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-07CD-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ARST0332 (Neoadjuvant ID)","valueDescription":"ARST0332 (Neoadjuvant ID)","ValueMeaning":{"publicId":"4903799","version":"1","preferredName":"ARST0332 (Neoadjuvant ID)","longName":"4903799","preferredDefinition":"COG Protocol ID ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Patients Under 30 Years of Age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-07D7-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-07F0-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ARST0332 (Adjuvant ID)","valueDescription":"ARST0332 (Adjuvant ID)","ValueMeaning":{"publicId":"4903800","version":"1","preferredName":"ARST0332 (Adjuvant ID)","longName":"4903800","preferredDefinition":"COG Protocol ID: ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Patients Under 30 Years of Age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-07FA-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-0813-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ARST0331 (VACx4/VAx12)","valueDescription":"ARST0331 (VACx4/VAx12)","ValueMeaning":{"publicId":"4903801","version":"1","preferredName":"ARST0331 (VACx4/VAx12)","longName":"4903801","preferredDefinition":"COG Protocol ID ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-081D-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-0836-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ARST0331 (VACx4/VA x4)","valueDescription":"ARST0331 (VACx4/VA x4)","ValueMeaning":{"publicId":"4903802","version":"1","preferredName":"ARST0331 (VACx4/VA x4)","longName":"4903802","preferredDefinition":"COG Protocol ID ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-0840-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-0859-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"D9602","valueDescription":"D9602","ValueMeaning":{"publicId":"4903803","version":"1","preferredName":"D9602","longName":"4903803","preferredDefinition":"COG Protocol ID D9602: Actinomycin D and VCR with or without CPM and RT, for Newly Diagnosed Patients with Low-Risk Embryonal/Botryoid Rhabdomyosarcoma: IRS-V Protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-0863-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-087C-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"D9803","valueDescription":"D9803","ValueMeaning":{"publicId":"4903804","version":"1","preferredName":"D9803","longName":"4903804","preferredDefinition":"COG Protocol ID D9803: Randomized Study of VCR, Actinomycin-D, and CPM (VAC) vs. VAC alternating with VCR, Topotecan, and CPM (VTC) for Patients with Intermediate Risk RMS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-0886-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B16B1A7-089F-15A5-E050-BB89AD436F4F","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"TSESU","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0331","valueDescription":"ACNS0331","ValueMeaning":{"publicId":"4908820","version":"1","preferredName":"ACNS0331","longName":"4908820","preferredDefinition":"COG Protocol ID ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B546673-AAC2-9D7F-E050-BB89AD434516","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B546673-AADA-9D7F-E050-BB89AD434516","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0221","valueDescription":"ACNS0221","ValueMeaning":{"publicId":"4908818","version":"1","preferredName":"ACNS0221","longName":"4908818","preferredDefinition":"COG Protocol ID ACNS0221: A Phase II Study of Conformal Radiotherapy in Patients with Low Grade Gliomas","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B546673-AA7C-9D7F-E050-BB89AD434516","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B546673-AA94-9D7F-E050-BB89AD434516","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0223","valueDescription":"ACNS0223","ValueMeaning":{"publicId":"4908819","version":"1","preferredName":"ACNS0223","longName":"4908819","preferredDefinition":"COG Protocol ID ACNS0223: Pilot Study Using Carboplatin, Vincristine and Temozolomide for Children Less Than or Equal to 10 Years of Age with Progressive/Symptomatic Low-Grade Gliomas","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B546673-AA9F-9D7F-E050-BB89AD434516","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B546673-AAB7-9D7F-E050-BB89AD434516","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0121 (Treatment 3)","valueDescription":"ACNS0121 (Treatment 3)","ValueMeaning":{"publicId":"4908824","version":"1","preferredName":"ACNS0121 (Treatment 3)","longName":"4908824","preferredDefinition":"COG Protocol ACNS0121 (Treatment 3): A Phase II Trial of Conformal RT for Pediatric Patients with Localized Ependymoma, Chemotherapy prior to 2nd Surgery for Incompletely Resected Ependymoma and Observations for Completely Resected, Differentiated, Supratentorial Ependymom","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B546673-AB33-9D7F-E050-BB89AD434516","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B546673-AB4C-9D7F-E050-BB89AD434516","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0121 (Treatment 2)","valueDescription":"ACNS0121 (Treatment 2)","ValueMeaning":{"publicId":"4908825","version":"1","preferredName":"ACNS0121 (Treatment 2)","longName":"4908825","preferredDefinition":"COG Protocol ID ACNS0121 (Treatment 2): A Phase II Trial of Conformal RT for Pediatric Patients with Localized Ependymoma, Chemotherapy prior to 2nd Surgery for Incompletely Resected Ependymoma and Observations for Completely Resected, Differentiated, Supratentorial Ependymom","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B546673-AB56-9D7F-E050-BB89AD434516","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B546673-AB6F-9D7F-E050-BB89AD434516","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0121 (Treatment 1)","valueDescription":"ACNS0121 (Treatment 1)","ValueMeaning":{"publicId":"4908826","version":"1","preferredName":"ACNS0121 (Treatment 1)","longName":"4908826","preferredDefinition":"COG Protocol ID ACNS0121 (Treatment 1): A Phase II Trial of Conformal RT for Pediatric Patients with Localized Ependymoma, Chemotherapy prior to 2nd Surgery for Incompletely Resected Ependymoma and Observations for Completely Resected, Differentiated, Supratentorial Ependymom","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B546673-AB79-9D7F-E050-BB89AD434516","latestVersionIndicator":"Yes","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B546673-AB92-9D7F-E050-BB89AD434516","beginDate":"2015-07-20","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-20","modifiedBy":"ONEDATA","dateModified":"2015-07-20","deletedIndicator":"No"},{"value":"ACNS0831 (cRT)","valueDescription":"ACNS0831 (cRT followed by maintenance chemotherapy or observation)","ValueMeaning":{"publicId":"4915373","version":"1","preferredName":"ACNS0831 (cRT followed by maintenance chemotherapy or observation)","longName":"4915373","preferredDefinition":"ACNS0831 (cRT followed by maintenance chemotherapy or observation): Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-65C5-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D21E83F-10C7-F641-E050-BB89AD4353A0","beginDate":"2015-07-21","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"ONEDATA","dateModified":"2015-08-12","deletedIndicator":"No"},{"value":"ACNS0831 (Induction Chemotherapy)","valueDescription":"ACNS0831 (Induction Chemotherapy followed by one or more of the following: surgery, cRT, maintenance chemotherapy, or observation)","ValueMeaning":{"publicId":"4915374","version":"1","preferredName":"ACNS0831 (Induction Chemotherapy followed by one or more of the following: surgery, cRT, maintenance chemotherapy, or observation)","longName":"4915374","preferredDefinition":"ACNS0831 (Induction Chemotherapy followed by one or more of the following: surgery, cRT, maintenance chemotherapy, or observation): Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B64EE41-65E8-3B0B-E050-BB89AD433710","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D21E83F-10DB-F641-E050-BB89AD4353A0","beginDate":"2015-07-20","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"ONEDATA","dateModified":"2015-08-12","deletedIndicator":"No"},{"value":"AAML1031 Arm A - High Risk","valueDescription":"AAML1031 Arm A - High Risk","ValueMeaning":{"publicId":"4947996","version":"1","preferredName":"AAML1031 Arm A - High Risk","longName":"4947996","preferredDefinition":"AAML1031 Arm A - High Risk: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D233027-6CB4-844A-E050-BB89AD436BF8","latestVersionIndicator":"Yes","beginDate":"2015-08-12","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D233027-6CCD-844A-E050-BB89AD436BF8","beginDate":"2015-07-20","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"ONEDATA","dateModified":"2015-08-12","deletedIndicator":"No"},{"value":"AAML1031 Arm A - Low Risk","valueDescription":"AAML1031 Arm A - Low Risk","ValueMeaning":{"publicId":"4947997","version":"1","preferredName":"AAML1031 Arm A - Low Risk","longName":"4947997","preferredDefinition":"AAML1031 Arm A - Low Risk: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D233027-6CD7-844A-E050-BB89AD436BF8","latestVersionIndicator":"Yes","beginDate":"2015-08-12","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D233027-6CF0-844A-E050-BB89AD436BF8","beginDate":"2015-07-20","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"ONEDATA","dateModified":"2015-08-12","deletedIndicator":"No"},{"value":"AAML1031 Arm B - High Risk","valueDescription":"AAML1031 Arm B - High Risk","ValueMeaning":{"publicId":"4947998","version":"1","preferredName":"AAML1031 Arm B - High Risk","longName":"4947998","preferredDefinition":"AAML1031 Arm B - High Risk: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D233027-6CFA-844A-E050-BB89AD436BF8","latestVersionIndicator":"Yes","beginDate":"2015-08-12","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D233027-6D13-844A-E050-BB89AD436BF8","beginDate":"2015-07-20","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"ONEDATA","dateModified":"2015-08-12","deletedIndicator":"No"},{"value":"AAML1031 Arm B - Low Risk","valueDescription":"AAML1031 Arm B - Low Risk","ValueMeaning":{"publicId":"4947999","version":"1","preferredName":"AAML1031 Arm B - Low Risk","longName":"4947999","preferredDefinition":"AAML1031 Arm B - Low Risk: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D233027-6D1D-844A-E050-BB89AD436BF8","latestVersionIndicator":"Yes","beginDate":"2015-08-12","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D233027-6D36-844A-E050-BB89AD436BF8","beginDate":"2015-07-20","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-12","modifiedBy":"ONEDATA","dateModified":"2015-08-12","deletedIndicator":"No"},{"value":"AALL1231 (Arm A)","valueDescription":"AALL1231 (Arm A)","ValueMeaning":{"publicId":"6334890","version":"1","preferredName":"AALL1231 (Arm A)","longName":"6334890","preferredDefinition":"AALL1231 (Arm A): A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-E9AB-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-E9C4-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL1131 (Dasatinib Arm)","valueDescription":"AALL1131 (Dasatinib Arm)","ValueMeaning":{"publicId":"6334891","version":"1","preferredName":"AALL1131 (Dasatinib Arm)","longName":"6334891","preferredDefinition":"AALL1131 (Dasatinib Arm): A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-E9CE-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-E9E7-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL1131 (VHR CONTROL ARM)","valueDescription":"AALL1131 (VHR CONTROL ARM)","ValueMeaning":{"publicId":"6334892","version":"1","preferredName":"AALL1131 (VHR CONTROL ARM)","longName":"6334892","preferredDefinition":"AALL1131 (VHR CONTROL ARM): A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-E9F1-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EA0A-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL1131 (HR ARM A)","valueDescription":"AALL1131 (HR ARM A)","ValueMeaning":{"publicId":"6334893","version":"1","preferredName":"AALL1131 (HR ARM A)","longName":"6334893","preferredDefinition":"AALL1131 (HR ARM A): A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EA14-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EA2D-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL1131 (HRDS)","valueDescription":"AALL1131 (HRDS)","ValueMeaning":{"publicId":"6334894","version":"1","preferredName":"AALL1131 (HRDS)","longName":"6334894","preferredDefinition":"AALL1131 (HRDS): A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EA37-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EA50-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0932 (AR-Arm D)","valueDescription":"AALL0932 (AR-Arm D)","ValueMeaning":{"publicId":"6334895","version":"1","preferredName":"AALL0932 (AR-Arm D)","longName":"6334895","preferredDefinition":"AALL0932 (AR-Arm D): Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EA5A-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EA73-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0932 (AR-Arm C)","valueDescription":"AALL0932 (AR-Arm C)","ValueMeaning":{"publicId":"6334896","version":"1","preferredName":"AALL0932 (AR-Arm C)","longName":"6334896","preferredDefinition":"AALL0932 (AR-Arm C): Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EA7D-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EA96-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0932 (AR-Arm B)","valueDescription":"AALL0932 (AR-Arm B)","ValueMeaning":{"publicId":"6334897","version":"1","preferredName":"AALL0932 (AR-Arm B)","longName":"6334897","preferredDefinition":"AALL0932 (AR-Arm B): Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EAA0-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EAB9-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0932 (AR-Arm A)","valueDescription":"AALL0932 (AR-Arm A)","ValueMeaning":{"publicId":"6334898","version":"1","preferredName":"AALL0932 (AR-Arm A)","longName":"6334898","preferredDefinition":"AALL0932 (AR-Arm A): Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EAC3-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EADC-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0932 (LR-M)","valueDescription":"AALL0932 (LR-M)","ValueMeaning":{"publicId":"6334899","version":"1","preferredName":"AALL0932 (LR-M)","longName":"6334899","preferredDefinition":"AALL0932 (LR-M): Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EAE6-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EAFF-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0932 (LR-C)","valueDescription":"AALL0932 (LR-C)","ValueMeaning":{"publicId":"6334900","version":"1","preferredName":"AALL0932 (LR-C)","longName":"6334900","preferredDefinition":"AALL0932 (LR-C): Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EB09-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EB22-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0932 (SRDS)","valueDescription":"AALL0932 (SRDS)","ValueMeaning":{"publicId":"6334901","version":"1","preferredName":"AALL0932 (SRDS)","longName":"6334901","preferredDefinition":"AALL0932 (SRDS): Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EB2C-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EB45-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0631","valueDescription":"AALL0631","ValueMeaning":{"publicId":"6334902","version":"1","preferredName":"AALL0631","longName":"6334902","preferredDefinition":"AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431, NSC#617807)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EB4F-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EB68-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0434: Arm D (HD MTX with nelarabine)","valueDescription":"AALL0434: Arm D (HD MTX with nelarabine)","ValueMeaning":{"publicId":"6334903","version":"1","preferredName":"AALL0434: Arm D (HD MTX with nelarabine)","longName":"6334903","preferredDefinition":"AALL0434: Arm D (HD MTX with nelarabine): Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EB72-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EB8B-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0434: Arm C (HD MTX; no nelarabine)","valueDescription":"AALL0434: Arm C (HD MTX; no nelarabine)","ValueMeaning":{"publicId":"6334904","version":"1","preferredName":"AALL0434: Arm C (HD MTX; no nelarabine)","longName":"6334904","preferredDefinition":"AALL0434: Arm C (HD MTX; no nelarabine): Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EB95-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EBAE-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0434: Arm B (Capizzi MTX with nelarabine)","valueDescription":"AALL0434: Arm B (Capizzi MTX with nelarabine)","ValueMeaning":{"publicId":"6334905","version":"1","preferredName":"AALL0434: Arm B (Capizzi MTX with nelarabine)","longName":"6334905","preferredDefinition":"AALL0434: Arm B (Capizzi MTX with nelarabine): Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EBB8-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EBD1-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"ALLL0434: Arm A (Capizzi MTX; no nelarabine)","valueDescription":"ALLL0434: Arm A (Capizzi MTX; no nelarabine)","ValueMeaning":{"publicId":"6334906","version":"1","preferredName":"ALLL0434: Arm A (Capizzi MTX; no nelarabine)","longName":"6334906","preferredDefinition":"ALLL0434: Arm A (Capizzi MTX; no nelarabine): Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EBDB-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EBF4-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0331","valueDescription":"AALL0331","ValueMeaning":{"publicId":"6334907","version":"1","preferredName":"AALL0331","longName":"6334907","preferredDefinition":"AALL0331: Standard Risk B-precursor Acute Lymphoblastic Leukemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EBFE-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EC17-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0232 (Dexamethasone, HDMTX)","valueDescription":"AALL0232 (Dexamethasone, HDMTX)","ValueMeaning":{"publicId":"6334908","version":"1","preferredName":"AALL0232 (Dexamethasone, HDMTX)","longName":"6334908","preferredDefinition":"AALL0232 (Dexamethasone, HDMTX): High Risk B-precursor Acute Lymphoblastic Leukemia (ALL)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EC21-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EC3A-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0232 (Prednisone, HDMTX)","valueDescription":"AALL0232 (Prednisone, HDMTX)","ValueMeaning":{"publicId":"6334909","version":"1","preferredName":"AALL0232 (Prednisone, HDMTX)","longName":"6334909","preferredDefinition":"AALL0232 (Prednisone, HDMTX): High Risk B-precursor Acute Lymphoblastic Leukemia (ALL)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EC44-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EC5D-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL0031","valueDescription":"AALL0031","ValueMeaning":{"publicId":"6334910","version":"1","preferredName":"AALL0031","longName":"6334910","preferredDefinition":"AALL0031: A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (STI-571 (GLEEVEC) NSC#716051/IND#61135)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6E7A56F1-EC67-3247-E053-F662850A1BC9","latestVersionIndicator":"Yes","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E7A56F1-EC80-3247-E053-F662850A1BC9","beginDate":"2018-06-12","endDate":null,"createdBy":"GONTIJOP","dateCreated":"2018-06-12","modifiedBy":"ONEDATA","dateModified":"2018-06-12","deletedIndicator":"No"},{"value":"AALL1631 (High Risk Arm)","valueDescription":"AALL1631 (High Risk Arm)","ValueMeaning":{"publicId":"6289550","version":"1","preferredName":"AALL1631 (High Risk Arm)","longName":"6289550","preferredDefinition":"AALL1631 (High Risk Arm): International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C47CDEE-24CA-28DE-E053-F662850A6987","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C47CDEE-24E3-28DE-E053-F662850A6987","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","deletedIndicator":"No"},{"value":"AALL1631 (Arm B)","valueDescription":"AALL1631 (Arm B)","ValueMeaning":{"publicId":"6289551","version":"1","preferredName":"AALL1631 (Arm B)","longName":"6289551","preferredDefinition":"AALL1631 (Arm B): International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C47CDEE-24ED-28DE-E053-F662850A6987","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C47CDEE-2506-28DE-E053-F662850A6987","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","deletedIndicator":"No"},{"value":"AALL1631 (Arm A)","valueDescription":"AALL1631 (Arm A)","ValueMeaning":{"publicId":"6289552","version":"1","preferredName":"AALL1631 (Arm A)","longName":"6289552","preferredDefinition":"AALL1631 (Arm A): International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C47CDEE-2510-28DE-E053-F662850A6987","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C47CDEE-2529-28DE-E053-F662850A6987","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","deletedIndicator":"No"},{"value":"AALL15P1","valueDescription":"AALL15P1","ValueMeaning":{"publicId":"6289553","version":"1","preferredName":"AALL15P1","longName":"6289553","preferredDefinition":"AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C47CDEE-2533-28DE-E053-F662850A6987","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C47CDEE-254C-28DE-E053-F662850A6987","beginDate":"2018-05-15","endDate":null,"createdBy":"HAMMA","dateCreated":"2018-05-15","modifiedBy":"ONEDATA","dateModified":"2018-05-15","deletedIndicator":"No"},{"value":"ACNS1821","valueDescription":"Study Protocol Identifier","ValueMeaning":{"publicId":"6686329","version":"1","preferredName":"Study Protocol Identifier","longName":"6686329","preferredDefinition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.: One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Study Protocol","conceptCode":"C70817","definition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A624CD-3206-79ED-E053-F662850A6403","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DC831EE-E1C5-7421-E053-F662850AF6B5","beginDate":"2020-02-04","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-02-04","modifiedBy":"ONEDATA","dateModified":"2020-02-04","deletedIndicator":"No"},{"value":"None of the above","valueDescription":"None of the Above","ValueMeaning":{"publicId":"5913672","version":"1","preferredName":"None of the Above","longName":"5913672","preferredDefinition":"None of the choices above are suitable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None of the Above","conceptCode":"C133298","definition":"None of the choices above are suitable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5499ACEF-10D1-1155-E053-F662850A3955","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-18","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A6349E-1623-7C59-E053-F662850ADE6B","beginDate":"2019-04-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"ACNS1723","valueDescription":"Study Protocol Identifier","ValueMeaning":{"publicId":"6686328","version":"1","preferredName":"Study Protocol Identifier","longName":"6686328","preferredDefinition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.: One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Study Protocol","conceptCode":"C70817","definition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A624CD-31E3-79ED-E053-F662850A6403","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A624CD-31FC-79ED-E053-F662850A6403","beginDate":"2019-04-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"ACNS1721","valueDescription":"Study Protocol Identifier","ValueMeaning":{"publicId":"6686329","version":"1","preferredName":"Study Protocol Identifier","longName":"6686329","preferredDefinition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.: One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Study Protocol","conceptCode":"C70817","definition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A624CD-3206-79ED-E053-F662850A6403","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85A624CD-321E-79ED-E053-F662850A6403","beginDate":"2019-04-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","deletedIndicator":"No"},{"value":"ACNS1833","valueDescription":"ACNS1833","ValueMeaning":{"publicId":"6823803","version":"1","preferredName":"ACNS1833","longName":"6823803","preferredDefinition":"ACNS1833 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5F523F-F47B-397D-E053-F662850A2ED9","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5F523F-F494-397D-E053-F662850A2ED9","beginDate":"2019-07-23","endDate":null,"createdBy":"COBARRUBIAK","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"ACNS2021","valueDescription":"Study Protocol Identifier","ValueMeaning":{"publicId":"6686329","version":"1","preferredName":"Study Protocol Identifier","longName":"6686329","preferredDefinition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.: One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Study Protocol","conceptCode":"C70817","definition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A624CD-3206-79ED-E053-F662850A6403","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7092890-1E05-40DF-E053-4EBD850AC739","beginDate":"2020-06-01","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-06-01","modifiedBy":"ONEDATA","dateModified":"2020-06-01","deletedIndicator":"No"},{"value":"ACNS2031","valueDescription":"ACNS2031","ValueMeaning":{"publicId":"7850265","version":"1","preferredName":"ACNS2031","longName":"7850265","preferredDefinition":"ACNS2031","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2ADE7DB-8731-3D77-E053-4EBD850A7B8F","latestVersionIndicator":"Yes","beginDate":"2021-12-08","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-08","modifiedBy":"ONEDATA","dateModified":"2021-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D2ADE7DB-874A-3D77-E053-4EBD850A7B8F","beginDate":"2021-12-08","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-08","modifiedBy":"ONEDATA","dateModified":"2021-12-08","deletedIndicator":"No"},{"value":"ACNS1422","valueDescription":"Study Protocol Identifier","ValueMeaning":{"publicId":"6686329","version":"1","preferredName":"Study Protocol Identifier","longName":"6686329","preferredDefinition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.: One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Study Protocol","conceptCode":"C70817","definition":"The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A624CD-3206-79ED-E053-F662850A6403","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2019-04-03","modifiedBy":"ONEDATA","dateModified":"2019-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD19FD39-5B9D-75EF-E053-4EBD850AB637","beginDate":"2022-04-20","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2022-04-20","modifiedBy":"ONEDATA","dateModified":"2022-04-20","deletedIndicator":"No"},{"value":"AALL1732","valueDescription":null,"ValueMeaning":{"publicId":"7412472","version":"1","preferredName":"COG AALL1732","longName":"7412472v1.00","preferredDefinition":"COG NCT03959085","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6CBDDA-BE00-27C9-E053-4EBD850A692A","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2023-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDBF3D46-0F7B-7A3D-E053-731AD00AD4D4","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"AALL1231","valueDescription":null,"ValueMeaning":{"publicId":"12097125","version":"1","preferredName":"AALL1231","longName":"12097125v1.00","preferredDefinition":"AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDBF3D46-0F77-7A3D-E053-731AD00AD4D4","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDBF3D46-0F7C-7A3D-E053-731AD00AD4D4","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"C10403","valueDescription":null,"ValueMeaning":{"publicId":"12097126","version":"1","preferredName":"C10403","longName":"12097126v1.00","preferredDefinition":"C10403: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDBF3D46-0F78-7A3D-E053-731AD00AD4D4","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDBF3D46-0F7D-7A3D-E053-731AD00AD4D4","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"A041501","valueDescription":null,"ValueMeaning":{"publicId":"12097127","version":"1","preferredName":"A041501","longName":"12097127v1.00","preferredDefinition":"A041501: A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDBF3D46-0F79-7A3D-E053-731AD00AD4D4","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDBF3D46-0F7E-7A3D-E053-731AD00AD4D4","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"AALL0232","valueDescription":null,"ValueMeaning":{"publicId":"4626602","version":"1","preferredName":"AALL0232","longName":"4626602","preferredDefinition":"AALL0232","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09BB4635-43CC-5E75-E050-BB89AD4329AC","latestVersionIndicator":"Yes","beginDate":"2014-12-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-12-08","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDBF3D46-0F7F-7A3D-E053-731AD00AD4D4","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"AALL0434","valueDescription":null,"ValueMeaning":{"publicId":"12097128","version":"1","preferredName":"AALL0434","longName":"12097128v1.00","preferredDefinition":"AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDBF3D46-0F7A-7A3D-E053-731AD00AD4D4","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDBF3D46-0F80-7A3D-E053-731AD00AD4D4","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"AALL1131","valueDescription":null,"ValueMeaning":{"publicId":"7412474","version":"1","preferredName":"AALL1131","longName":"7412474","preferredDefinition":"AALL1131","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE6CBDDA-BE46-27C9-E053-4EBD850A692A","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDC06792-D4B3-239C-E053-731AD00AC427","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"AALL1631","valueDescription":null,"ValueMeaning":{"publicId":"12097129","version":"1","preferredName":"AALL1631","longName":"12097129v1.00","preferredDefinition":"AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC06792-D4B2-239C-E053-731AD00AC427","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDC06792-D4B4-239C-E053-731AD00AC427","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"ACNS1422","valueDescription":null,"ValueMeaning":{"publicId":"14478171","version":"1","preferredName":"ACNS1422","longName":"14478171v1.00","preferredDefinition":"ACNS1422","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A013-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A01D-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1721","valueDescription":null,"ValueMeaning":{"publicId":"14478172","version":"1","preferredName":"ACNS1721","longName":"14478172v1.00","preferredDefinition":"ACNS1721","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A014-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A01E-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1723","valueDescription":null,"ValueMeaning":{"publicId":"14478173","version":"1","preferredName":"ACNS1723","longName":"14478173v1.00","preferredDefinition":"ACNS1723","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A015-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A01F-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1821","valueDescription":null,"ValueMeaning":{"publicId":"14478174","version":"1","preferredName":"ACNS1821","longName":"14478174v1.00","preferredDefinition":"ACNS1821","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A016-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A020-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1831 (Arm 2)","valueDescription":null,"ValueMeaning":{"publicId":"14478176","version":"1","preferredName":"ACNS1831 (Arm 2)","longName":"14478176v1.00","preferredDefinition":"ACNS1831 (Arm 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A018-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A021-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1833 (Arm 1)","valueDescription":null,"ValueMeaning":{"publicId":"14478177","version":"1","preferredName":"ACNS1833 (Arm 1)","longName":"14478177v1.00","preferredDefinition":"ACNS1833 (Arm 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A019-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A022-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1833 (Arm 2)","valueDescription":null,"ValueMeaning":{"publicId":"14478178","version":"1","preferredName":"ACNS1833 (Arm 2)","longName":"14478178v1.00","preferredDefinition":"ACNS1833 (Arm 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A01A-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A023-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1931 (Arm 1)","valueDescription":null,"ValueMeaning":{"publicId":"14478179","version":"1","preferredName":"ACNS1931 (Arm 1)","longName":"14478179v1.00","preferredDefinition":"ACNS1931 (Arm 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A01B-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A024-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1931 (Arm 2)","valueDescription":null,"ValueMeaning":{"publicId":"14478180","version":"1","preferredName":"ACNS1931 (Arm 2)","longName":"14478180v1.00","preferredDefinition":"ACNS1931 (Arm 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A01C-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A025-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS1831 (Arm 1)","valueDescription":null,"ValueMeaning":{"publicId":"14478175","version":"1","preferredName":"ACNS1831 (Arm 1)","longName":"14478175v1.00","preferredDefinition":"ACNS1831 (Arm 1)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B44B-A017-1725-E063-731AD00AE6F5","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B44B-A026-1725-E063-731AD00AE6F5","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS2021","valueDescription":null,"ValueMeaning":{"publicId":"14103918","version":"1","preferredName":"ACNS2021","longName":"14103918v1.00","preferredDefinition":"A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular and Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00DFBF65-BD50-0A43-E063-731AD00A713F","latestVersionIndicator":"Yes","beginDate":"2023-07-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-19","modifiedBy":"GDEEN","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B8D7-5B0F-1B34-E063-731AD00A3802","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS2031 (Average Risk)","valueDescription":null,"ValueMeaning":{"publicId":"14478181","version":"1","preferredName":"ACNS2031 (Average Risk)","longName":"14478181v1.00","preferredDefinition":"ACNS2031 (Average Risk)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B8D7-5B0D-1B34-E063-731AD00A3802","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B8D7-5B10-1B34-E063-731AD00A3802","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ACNS2031 (Low Risk)","valueDescription":null,"ValueMeaning":{"publicId":"14478182","version":"1","preferredName":"ACNS2031 (Low Risk)","longName":"14478182v1.00","preferredDefinition":"ACNS2031 (Low Risk)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7B8D7-5B0E-1B34-E063-731AD00A3802","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7B8D7-5B11-1B34-E063-731AD00A3802","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008529","version":"1","preferredName":"Research Protocols","preferredDefinition":"the identification of cancer research protocols.","longName":"RSCH_PROT","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECC2BE-2F27-348A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233101","version":"1","preferredName":"Number","preferredDefinition":"Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.","longName":"C25337","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Number","conceptCode":"C25337","definition":"A numeral or string of numerals expressing value, quantity, or identification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F920A342-1134-2A6A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B16B1A7-05FC-15A5-E050-BB89AD436F4F","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"COG Anti-Cancer Therapeutic r","type":"Preferred Question Text","description":"COG Anti-Cancer Therapeutic regimen administered:","url":null,"context":"COG"},{"name":"COG CRF Text 10","type":"Alternate Question Text","description":"Specify COG protocol number:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Which protocol/regimen:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B171FA1-EFF8-7183-E050-BB89AD430EB3","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-17","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":"2022.11.17 AQT added for ticket request CADSR0001705. ak","unresolvedIssues":null,"deletedIndicator":"No"}}